For physicians who use proton pump inhibitors in a cavalier manner, a recent review (CM Stark, CM Nylund. J Pediatr 168: 16-22) provides a sobering reassessment of the potential side effects and potential complications of proton pump inhibitors (PPIs). After finishing the article, the impression left was of a lawyer putting these medications on trial for high crimes and misdemeanors.
Here were the key points:
Infectious disease: PPI-induced hypochloridia is known to alter the gastrointestinal bacteria motif, allowing certain normally absent or depleted pathogenetic microorganisms to survive and proliferate. This can lead to all of the following:
- small bowel bacterial overgrowth
- increased gastrointestinal infections (including Clostridium difficile, Salmonella, Campylobacter, and acute viral gastroenteritis)
- pneumonia (particularly community acquired pneumonia and hospital acquired pneumonia)
- upper respiratory infections
- spontaneous bacterial peritonitis.
The magnitude of these associations is discussed in detail in the review.
Gastrointestinal disease: Use of PPIs has been associated with an increased incidence of the following:
- celiac disease which persisted after excluding prescriptions in the year preceding diagnosis (association does not prove causation)
- benign gastric fundic polyps
- rebound acid hypersecretion
Malabsorption: PPIs can affect absorption of multiple nutrients, though more studies are needed, particularly in the pediatric age group.
- calcium: “there is significant evidence to suggest that PPI use can alter calcium and bone metabolism…associated with an increased risk of hip fractures in older adults….It is reasonable to hypothesize that PPI administration during adolescence and early adulthood could decrease an individual’s peak bone density.”
- magnesium: PPI have been hypothesized to affect magnesium absorption. “A study of 366 Canadian patients hospitalized with hypomagnesemia…found PPIs [were] associated with a 43% increased risk of hospitalization.” More studies are needed to determine the whether this risk is truly significant.
- iron, vitamin B12, and vitamin C absorption may be affected by PPI use.
- Cardiac: In adults, PPI use has been associated with adverse cardiac events. The pathophysiology could have been pediatric implications. PPIs can increase asymmetrical dimethylarginine (ADMA) which is an endogenous inhibitor of nitric oxide synthase.
- Renal: PPIs have been associated with cases of acute interstitial nephritis
- Microbiome: “PPIs alter the microbiome.” Decreased diversity of the microbiome has been associated with a large number of medical conditions, including irritable bowel syndrome, inflammatory bowel disease, nonalcoholic fatty liver disease, necrotizing enterocolitis as well as many non-gastrointestinal conditions. “The temporality of dysbiosis and subsequent disease development has not been explored fully for most conditions.”
My take: PPIs can be life-saving and disease-altering medications. At the same time, (per authors) “PPIs should not be prescribed without consideration for all short- and long-term side effects.”
Related blog posts:
- No Effect of Proton Pump Inhibitors and Irritability on Crying …
- PPI Side Effects: “Dissecting the Evidence” | gutsandgrowth
- How Proton Pump Inhibitors Can Cause Infections …
- Do medicines work for GERD infants? | gutsandgrowth
- “Decision Fatigue” & 1000 Posts | gutsandgrowth
- GERD Treatment in Infants: “Friend or Foe” | gutsandgrowth
Jay – interesting provocative piece today – more info for the PPI-haters out there.
To get the “data”, I would recommend that people register and listen in to the following Webinar for CME credit…Ben
LIVE WEBINAR: January 26, 2016: 8 – 9:15 P.M. EST
Proton Pump Inhibitors: To use or not to use… That is the question!
This program, geared specifically for pediatric gastroenterologists, will arm the specialist with essential education to ensure clarity surrounding current indications for use of proton pump inhibitors in children, as well as a growing understanding of risks associated with their use.
Jenifer R Lightdale, MD, MPH Professor of Pediatrics University of Massachusetts Medical School, Worcester, MA
Carlo Di Lorenzo, MD Professor of Pediatrics, The Ohio State University
Nationwide Children’s Hospital, Columbus, OH
Jose Garza, MD
Assistant Professor of Pediatrics Children’s Center for Digestive Health Care, LLC, Atlanta, GA
Benjamin D. Gold, MD Professor of Pediatrics and Microbiology
Children’s Center for Digestive Health Care, LLC, Atlanta, GA
Rachel Rosen, MD
Assistant Professor of Pediatrics Harvard Medical School, Boston, MA
Henry Lin, MD, Assistant Professor of Pediatrics, University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, PA
NASPGHAN designates this activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM
Pingback: Good Press for PPIs | gutsandgrowth
Pingback: Proton Pump Inhibitors Webinar | gutsandgrowth
Pingback: Does Reflux Lead to Increased Aspiration Pneumonia? | gutsandgrowth
Pingback: Salivary Pepsin Doesn’t Pass Muster for Evaluation of Reflux | gutsandgrowth
Pingback: Better to Do a Coin Toss than an ENT Examination to Determine Reflux | gutsandgrowth
Pingback: Deconstructing PPI-Associated Risks with Nearly 8 Billion Data Points and More on COVID-19 GI Symptoms (Video) | gutsandgrowth
Pingback: Reducing Inappropriate Proton Pump Inhibitor Usage & U.S. Children with COVID-19 | gutsandgrowth